Background We hypothesized that the clinical course of venous thromboembolism in patients with active cancer may differ according to the specificities of primary tumor site. Aim and Methods We used data from RIETE (international registry of patients with venous thromboembolism) to compare the clinical venous thromboembolism-related outcomes during the course of anticoagulation in patients with one of the 4 more frequent cancers (breast, prostate, colorectal, or lung cancer). Results As of September 2014, 3947 cancer patients were recruited, of whom 938 had breast, 629 prostate, 1189 colorectal, and 1191 lung cancer. Overall, 55% had metastatic disease (42%, 36%, 53%, and 72%, respectively). During the course of anticoagulant therapy (mean duration, 139 days), the rate of thromboembolic recurrences was similar to the rate of major bleeding in patients with breast (5.6 [95% confidence interval (CI), 3.8-8.1] vs 4.1 [95% CI, 2.7-5.9] events per 100 patient-years) or colorectal cancer (10 [95% CI, 7.6-13] vs 12 [95% CI, 9.4-15] per 100 patient-years). In contrast, in patients with prostate cancer, the rate of venous thromboembolic recurrences was half the rate of major bleeding (6.9 [95% CI, 4.4-10] vs 13 [95% CI, 9.2-17] events per 100 patient-years), whereas in those with lung cancer, the rate of thromboembolic recurrences was twofold higher than the rate of major bleeding (27 [95% CI, 22-23] vs 11 [95% CI, 8.6-15] per 100 patient-years). Conclusions Significant differences in the clinical profile of venous thromboembolic-related outcomes were observed according to the site of cancer. These findings suggest the development of cancer-specific anticoagulant strategies as an area for further research.
The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site / Mahe, I.; Chidiac, J.; Bertoletti, L.; Font, C.; Trujillo-Santos, J.; Peris, M.; Perez Ductor, C.; Nieto, S.; Grandone, E.; Monreal, M.; Aibar, M. A.; Arcelus, J. I.; Ballaz, A.; Barba, R.; Barron, M.; Barron-Andres, B.; Bascunana, J.; Blanco-Molina, A.; Bueso, T.; Casado, I.; Culla, A.; de Miguel, J.; del Toro, J.; Diaz-Peromingo, J. A.; Falga, C.; Fernandez-Capitan, C.; Font, L.; Gallego, P.; Garcia-Bragado, F.; Garcia-Brotons, P.; Gomez, V.; Gonzalez, J.; Grau, E.; Grimon, A.; Guirado, L.; Gutierrez, J.; Hernandez, G.; Hernandez-Blasco, L.; Isern, V.; Jara-Palomares, L.; Jaras, M. J.; Jimenez, D.; Lacruz, B.; Lecumberri, R.; Lobo, J. L.; Lopez-Jimenez, L.; Lopez-Reyes, R.; Lopez-Saez, J. B.; Lorente, M. A.; Lorenzo, A.; Madridano, O.; Marchena, P. J.; Martin-Antoran, J. M.; Martin-Martos, F.; Morales, M. V.; Nauffal, D.; Nieto, J. A.; Nieto, S.; Nunez, M. J.; Otalora, S.; Otero, R.; Pagan, B.; Pedrajas, J. M.; Perez, C.; Perez, G.; Peris, M. L.; Porras, J. A.; Ramirez, L.; Reig, O.; Riera, A.; Rivas, A.; Rodriguez-Davila, M. A.; Rosa, V.; Ruiz-Artacho, P.; Ruiz-Gimenez, N.; Ruiz-Martinez, C.; Samperiz, A.; Sala, C.; Sanz, O.; Soler, S.; Sopena, B.; Suarez, I.; Surinach, J. M.; Tiberio, G.; Tolosa, C.; Uresandi, F.; Valle, R.; Vela, J.; Villalta, J.; Malfante, P. C.; Verhamme, P.; Wells, P.; Hirmerova, J.; Maly, R.; Tomko, T.; Salgado, E.; Bura-Riviere, A.; Farge-Bancel, D.; Hij, A.; Merah, A.; Papadakis, M.; Braester, A.; Brenner, B.; Tzoran, I.; Apollonio, A.; Barillari, G.; Candeloro, G.; Ciammaichella, M.; Di Micco, P.; Ferrazzi, P.; Lessiani, G.; Lodigiani, C.; Mastroiacovo, D.; Pace, F.; Pinelli, M.; Prandoni, P.; Rota, L.; Tiraferri, E.; Tufano, A.; Visona, A.; Belovs, A.; Skride, A.; Moreira, M.; Ribeiro, J. L.; Sousa, M. S.; Bosevski, M.; Zdraveska, M.; Alatri, A.; Bounameaux, H.; Calanca, L.; Mazzolai, L.; Serrano, J. C.; Decousus, H.; Reis, A.. - In: THE AMERICAN JOURNAL OF MEDICINE. - ISSN 0002-9343. - 130:3(2017), pp. 337-347. [10.1016/j.amjmed.2016.10.017]
The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site
Gonzalez J.;Hernandez G.;Perez C.;Sala C.;Valle R.;Di Micco P.;Tufano A.;
2017
Abstract
Background We hypothesized that the clinical course of venous thromboembolism in patients with active cancer may differ according to the specificities of primary tumor site. Aim and Methods We used data from RIETE (international registry of patients with venous thromboembolism) to compare the clinical venous thromboembolism-related outcomes during the course of anticoagulation in patients with one of the 4 more frequent cancers (breast, prostate, colorectal, or lung cancer). Results As of September 2014, 3947 cancer patients were recruited, of whom 938 had breast, 629 prostate, 1189 colorectal, and 1191 lung cancer. Overall, 55% had metastatic disease (42%, 36%, 53%, and 72%, respectively). During the course of anticoagulant therapy (mean duration, 139 days), the rate of thromboembolic recurrences was similar to the rate of major bleeding in patients with breast (5.6 [95% confidence interval (CI), 3.8-8.1] vs 4.1 [95% CI, 2.7-5.9] events per 100 patient-years) or colorectal cancer (10 [95% CI, 7.6-13] vs 12 [95% CI, 9.4-15] per 100 patient-years). In contrast, in patients with prostate cancer, the rate of venous thromboembolic recurrences was half the rate of major bleeding (6.9 [95% CI, 4.4-10] vs 13 [95% CI, 9.2-17] events per 100 patient-years), whereas in those with lung cancer, the rate of thromboembolic recurrences was twofold higher than the rate of major bleeding (27 [95% CI, 22-23] vs 11 [95% CI, 8.6-15] per 100 patient-years). Conclusions Significant differences in the clinical profile of venous thromboembolic-related outcomes were observed according to the site of cancer. These findings suggest the development of cancer-specific anticoagulant strategies as an area for further research.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
